NIOSH logo and tagline

Request for Public Comment on NIOSH Initial Recommendations to Change the Status of Liraglutide and Pertuzumab on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings

NIOSH Docket Number 233-C, CDC-2020-0046

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), in the Department of Health and Human Services (HHS), requests public comment on two draft reevaluations with initial recommendations to change the status of two drugs, liraglutide and pertuzumab, on the NIOSH List of Antineoplastics and Other Hazardous Drugs in Healthcare Settings (List). The reevaluations were developed based on the process described in the NIOSH Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings.

Based on the reevaluations, the NIOSH initial recommendations are to remove liraglutide and pertuzumab from the List.

To view the notice and related materials, visit  and enter CDC-2020-0046 in the search field and click “Search.”

Public Comment Period

Comments will be accepted until 11:59 p.m. ET on February 15, 2024.  

Written comments, identified by CDC-2020-0046 and docket number NIOSH-233-C, may be submitted by any of the following methods:

  • Federal rulemaking portal: Follow the instructions for submitting comments.
  • Instructions: All submissions received must include the agency name and docket number. All relevant comments, including any personal information provided, will be posted without change to
  • Mail: NIOSH Docket Office
    1090 Tusculum Avenue
    Cincinnati, OH 45226-1998